Want to see TKNO full AI Analyst Report?
TKNO Stock Chart & Stats
$2.25
-$0.21(-2.33%)
At close: 4:00 PM EST
$2.25
-$0.21(-2.33%)
Day’s Range― - ―
52-Week Range$1.91 - $6.68
Previous CloseN/A
Volume51.57K
Average Volume (3M)318.88K
Market Cap
$290.59M
Enterprise Value$275.74M
Total Cash (Recent Filing)$4.31M
Total Debt (Recent Filing)$14.66M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Aug 12, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding53,614,030
10 Day Avg. Volume259,294
30 Day Avg. Volume318,881
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)2.96
Price to Sales (P/S)5.02
P/FCF Ratio-20.75
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue6.60
Enterprise Value/Gross Profit19.79
Enterprise Value/Ebitda-27.68
Forecast
1Y Price Target
$7.00Price Target Upside211.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$43.82M
Bulls Say, Bears Say
Bulls Say
Sticky Custom ManufacturingTeknova's mix of custom formulation and catalog sales creates high switching costs: customers qualify specific reagent formulations and tend to reorder. That stickiness supports recurring revenue, durable customer relationships and predictable demand as programs progress to larger, later-stage volumes.
Improving Revenue And Gross MarginSustained top-line growth and a recovery of gross margin into the mid‑30s materially improve unit economics. Stronger margins reduce the revenue required to reach adjusted EBITDA break‑even and indicate manufacturing/process improvements that, if sustained, support durable profitability as scale increases.
Manageable Leverage ProfileLow reported leverage for a development-stage company lowers refinancing and solvency risk, giving the firm more flexibility to invest in commercial expansion and manufacturing scale. A healthier balance-sheet stance supports survival through continued loss-making periods while pursuing growth.
Bears Say
Persistent GAAP LossesRepeated GAAP losses and sustained negative adjusted EBITDA indicate the business has not yet converted revenue growth into profitability. Continued losses erode equity, increase dependence on external funding, and raise the risk that scaling efforts may be interrupted or diluted before sustainable profits are achieved.
Negative Operating And Free Cash FlowOngoing negative operating and free cash flow require recurring financing or curtailed investment. With cash of ~$17.8M, borrowings ~$13.2M, and a projected sub‑$10M outflow for 2026, the firm's runway and ability to fund commercial or capacity investments are constrained absent improved cash conversion or external capital.
High Fixed Costs And Revenue LumpinessA high fixed-cost structure and low marginal cash conversion reduce the cash benefit from incremental revenue, slowing the path to break‑even. Coupled with lumpiness from large, uneven orders in Clinical Solutions, this raises uncertainty around timing of profitability and cash-flow stability as the business scales.
Alpha Teknova News
TKNO FAQ
What was Alpha Teknova’s price range in the past 12 months?
Alpha Teknova lowest stock price was $1.91 and its highest was $6.68 in the past 12 months.
What is Alpha Teknova’s market cap?
Alpha Teknova’s market cap is $290.59M.
When is Alpha Teknova’s upcoming earnings report date?
Alpha Teknova’s upcoming earnings report date is Aug 12, 2026 which is in 31 days.
How were Alpha Teknova’s earnings last quarter?
Alpha Teknova released its earnings results on May 06, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.093 by $0.013.
Is Alpha Teknova overvalued?
According to Wall Street analysts Alpha Teknova’s price is currently Undervalued.
Does Alpha Teknova pay dividends?
Alpha Teknova does not currently pay dividends.
What is Alpha Teknova’s EPS estimate?
Alpha Teknova’s EPS estimate is -0.08.
How many shares outstanding does Alpha Teknova have?
Alpha Teknova has 53,614,030 shares outstanding.
What happened to Alpha Teknova’s price movement after its last earnings report?
Alpha Teknova reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.093. Following the earnings report the stock price went up 9.89%.
Which hedge fund is a major shareholder of Alpha Teknova?
Currently, no hedge funds are holding shares in TKNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Teknova Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (211.11% Upside)
$7.00 (211.11% Upside)
Hedge Fund Trend
Increased
By 775.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.12%
12-Months-Change
Fundamentals
Return on Equity
-24.32%
Trailing 12-Months
Asset Growth
-13.45%
Trailing 12-Months
Company Description
Alpha Teknova
Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions. The company's product offerings encompass pre-filled media plates designed for cell growth and replication; liquid cell culture media and complementary supplements that promote cellular proliferation; and various molecular biology reagents used for the handling, rehydration, and purification of samples. Teknova caters to a diverse clientele within the life sciences arena, including pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostic businesses, and academic and governmental research facilities. Founded in 1996, Alpha Teknova's main office is situated in Hollister, California.
TKNO Company Deck
TKNO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive tone: the company reported solid top-line growth (13% YoY), a pronounced 85% increase in Clinical Solutions, improved gross margin and adjusted EBITDA, operational scaling initiatives, and disciplined commercial investments aimed at driving ~20% growth in 2027. However, material risks remain including a persistent GAAP net loss, continued negative adjusted EBITDA, modest Lab Essentials growth, high fixed-cost structure with a roughly 70% marginal cash drop-through, and dependence on broader biotech funding recovery. Management reiterated a conservative 2026 guide while outlining a credible plan for improved profitability and growth in 2027.View all TKNO earnings summariesTKNO Stock 12 Month Forecast
Average Price Target
$7.00
▲(211.11% Upside)
Technical Analysis
Ironwood Pharma
―
Lifecore Biomedical
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―
Ownership Overview
1.31% Insiders
2.50% Mutual Funds
7.18% Other Institutional Investors
86.67% Public Companies and
Individual Investors